Alkem Laboratories Limited

rs,

10th February, 2023 The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange of India Limited Excha

₹ 30,409 million

i today. Key highlights of Q3FY23 financial performance o  Total Revenue from Operations was ₹ 30,409 million, year-on-year growth of 16.1% India sales were ₹ 19,922 million, year-on-year growth of 9.7% Inte

16.1%

cial performance o  Total Revenue from Operations was ₹ 30,409 million, year-on-year growth of 16.1% India sales were ₹ 19,922 million, year-on-year growth of 9.7% International sales were ₹ 9,928 m

₹ 19,922 million

Total Revenue from Operations was ₹ 30,409 million, year-on-year growth of 16.1% India sales were ₹ 19,922 million, year-on-year growth of 9.7% International sales were ₹ 9,928 million, year-on-year growth of 28.8

9.7%

09 million, year-on-year growth of 16.1% India sales were ₹ 19,922 million, year-on-year growth of 9.7% International sales were ₹ 9,928 million, year-on-year growth of 28.8%  Earnings before Interest

₹ 9,928 million

of 16.1% India sales were ₹ 19,922 million, year-on-year growth of 9.7% International sales were ₹ 9,928 million, year-on-year growth of 28.8%  Earnings before Interest, Tax, Depreciation and Amortization (EBIT

28.8%

lion, year-on-year growth of 9.7% International sales were ₹ 9,928 million, year-on-year growth of 28.8%  Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 5,990 million, o

₹ 5,990 million

n-year growth of 28.8%  Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 5,990 million, o resulting in EBITDA margin of 19.7% vs. 19.0% in Q3FY22. EBITDA grew by 20.2% YoY  R&D ex

19.7%

ax, Depreciation and Amortization (EBITDA) was ₹ 5,990 million, o resulting in EBITDA margin of 19.7% vs. 19.0% in Q3FY22. EBITDA grew by 20.2% YoY  R&D expenses for the quarter was ₹ 1,297 million,

19.0%

iation and Amortization (EBITDA) was ₹ 5,990 million, o resulting in EBITDA margin of 19.7% vs. 19.0% in Q3FY22. EBITDA grew by 20.2% YoY  R&D expenses for the quarter was ₹ 1,297 million, or 4.3% o

20.2%

was ₹ 5,990 million, o resulting in EBITDA margin of 19.7% vs. 19.0% in Q3FY22. EBITDA grew by 20.2% YoY  R&D expenses for the quarter was ₹ 1,297 million, or 4.3% of total revenue from operations

₹ 1,297 million

margin of 19.7% vs. 19.0% in Q3FY22. EBITDA grew by 20.2% YoY  R&D expenses for the quarter was ₹ 1,297 million, or 4.3% of total revenue from operations compared to ₹ 1,449 million in Q3FY22 at 5.5% of total

Details of the conference call are as under

1

Dial in Details

1

Dial in Details

India : +91 22 6280 1149 / +91 22 7115 8050 International Toll Free USA UK Singapore Hong Kong : 1 866 746 2133 : 0 808 101 1573 : 800 101 2045 : 800 964 448 Express Join with Diamond Pass https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=3511653&linkS ecurityString=115d2253a9 You are requested to dial in 10 mins ahead of the scheduled start time. A transcript of this conference call will also be available on our website www.alkemlabs.com About Alkem Laboratories Ltd. Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in